Supplied strictly for in-vitro and laboratory research. Not for human or veterinary use. By ordering, you confirm you are a qualified researcher handling these materials per applicable regulations and safe lab practice.
CJC-1295 no DAC, also referred to as Modified GRF 1-29, is a growth-hormone-releasing factor analog supplied without the Drug Affinity Complex, which gives it a comparatively short half-life. It is studied for its role in stimulating the somatotropic axis and is often selected for research that calls for short-duration signaling profiles closer to natural pulsatile behavior.
The compound derives from sermorelin/GRF(1-29). The "modified" form introduces amino-acid substitutions, including D-Ala, Gln, Ala, and Leu, that improve enzymatic stability without adding the drug-affinity complex found in the DAC version. Removing that complex keeps its action brief, which is why it is studied for models focused on natural-pulse growth-hormone dynamics rather than sustained receptor activation.
CJC-1295 no DAC has been examined in endocrine models for GHRH-receptor agonism, enzymatic stability, growth-hormone-pulse stimulation, and IGF-1 modulation. Its short half-life is the defining research feature, letting investigators study a stabilized GHRH analog that still produces brief, pulse-like signaling. That makes it a useful comparator against longer-acting analogs when the experimental question is about the shape and timing of growth-hormone release rather than its total duration.
Manufactured in a controlled U.S. facility under strict compounding standards.
Every batch third-party tested with HPLC and mass spectrometry.
Orders dispatched same-day from our U.S. facility.
Reach out and get a response within minutes.
Everything you need to know about our products and processes.